JP2009541216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541216A5 JP2009541216A5 JP2009514642A JP2009514642A JP2009541216A5 JP 2009541216 A5 JP2009541216 A5 JP 2009541216A5 JP 2009514642 A JP2009514642 A JP 2009514642A JP 2009514642 A JP2009514642 A JP 2009514642A JP 2009541216 A5 JP2009541216 A5 JP 2009541216A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disease
- depression
- compound
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 208000007848 Alcoholism Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 206010041250 Social phobia Diseases 0.000 claims 4
- 208000019906 panic disease Diseases 0.000 claims 4
- 208000011117 substance-related disease Diseases 0.000 claims 4
- 229920002261 Corn starch Polymers 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 239000008120 corn starch Substances 0.000 claims 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229940079832 sodium starch glycolate Drugs 0.000 claims 3
- 229920003109 sodium starch glycolate Polymers 0.000 claims 3
- 239000008109 sodium starch glycolate Substances 0.000 claims 3
- 239000000454 talc Substances 0.000 claims 3
- 229910052623 talc Inorganic materials 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 208000017194 Affective disease Diseases 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010013654 Drug abuse Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 206010056465 Food craving Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010033664 Panic attack Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 201000009916 Postpartum depression Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 206010001584 alcohol abuse Diseases 0.000 claims 2
- 208000025746 alcohol use disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 238000011010 flushing procedure Methods 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 208000019899 phobic disease Diseases 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 231100000736 substance abuse Toxicity 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 229940033134 talc Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- VNGRUFUIHGGOOM-UHFFFAOYSA-N vortioxetine hydrobromide Chemical compound Br.CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 VNGRUFUIHGGOOM-UHFFFAOYSA-N 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80501406P | 2006-06-16 | 2006-06-16 | |
| DKPA200600824 | 2006-06-16 | ||
| US82666606P | 2006-09-22 | 2006-09-22 | |
| DKPA200601223 | 2006-09-22 | ||
| US86282606P | 2006-10-25 | 2006-10-25 | |
| DKPA200601384 | 2006-10-25 | ||
| DKPA200700427 | 2007-03-20 | ||
| PCT/DK2007/050075 WO2007144005A1 (en) | 2006-06-16 | 2007-06-15 | 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009295187A Division JP5702929B2 (ja) | 2006-06-16 | 2009-12-25 | 認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009541216A JP2009541216A (ja) | 2009-11-26 |
| JP2009541216A5 true JP2009541216A5 (enExample) | 2010-02-18 |
| JP4590013B2 JP4590013B2 (ja) | 2010-12-01 |
Family
ID=39722479
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009514642A Active JP4590013B2 (ja) | 2006-06-16 | 2007-06-15 | 認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン |
| JP2009295187A Active JP5702929B2 (ja) | 2006-06-16 | 2009-12-25 | 認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン |
| JP2012259835A Active JP5763609B2 (ja) | 2006-06-16 | 2012-11-28 | 認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン |
| JP2015118179A Active JP6101742B2 (ja) | 2006-06-16 | 2015-06-11 | 認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン |
| JP2016161018A Withdrawn JP2017008086A (ja) | 2006-06-16 | 2016-08-19 | 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン |
| JP2018150653A Active JP6724082B2 (ja) | 2006-06-16 | 2018-08-09 | 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン |
| JP2022182209A Withdrawn JP2023009175A (ja) | 2006-06-16 | 2022-11-15 | 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン |
| JP2024191303A Pending JP2025021476A (ja) | 2006-06-16 | 2024-10-31 | 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009295187A Active JP5702929B2 (ja) | 2006-06-16 | 2009-12-25 | 認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン |
| JP2012259835A Active JP5763609B2 (ja) | 2006-06-16 | 2012-11-28 | 認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン |
| JP2015118179A Active JP6101742B2 (ja) | 2006-06-16 | 2015-06-11 | 認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン |
| JP2016161018A Withdrawn JP2017008086A (ja) | 2006-06-16 | 2016-08-19 | 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン |
| JP2018150653A Active JP6724082B2 (ja) | 2006-06-16 | 2018-08-09 | 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン |
| JP2022182209A Withdrawn JP2023009175A (ja) | 2006-06-16 | 2022-11-15 | 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン |
| JP2024191303A Pending JP2025021476A (ja) | 2006-06-16 | 2024-10-31 | 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン |
Country Status (31)
| Country | Link |
|---|---|
| US (13) | US8722684B2 (enExample) |
| EP (2) | EP2439201B1 (enExample) |
| JP (8) | JP4590013B2 (enExample) |
| KR (3) | KR101445514B1 (enExample) |
| CN (3) | CN102614179B (enExample) |
| AR (1) | AR061481A1 (enExample) |
| AT (1) | ATE540941T1 (enExample) |
| AU (1) | AU2007260355B2 (enExample) |
| BR (3) | BR122020011920A2 (enExample) |
| CA (1) | CA2655212C (enExample) |
| CL (1) | CL2011001610A1 (enExample) |
| CY (1) | CY1112635T1 (enExample) |
| DK (1) | DK2044043T4 (enExample) |
| EA (1) | EA015287B1 (enExample) |
| ES (2) | ES2432102T3 (enExample) |
| FI (1) | FI2044043T5 (enExample) |
| HR (1) | HRP20120173T4 (enExample) |
| IL (1) | IL195511A (enExample) |
| MA (1) | MA30575B1 (enExample) |
| MX (1) | MX2008016141A (enExample) |
| MY (1) | MY150647A (enExample) |
| NO (1) | NO343929B1 (enExample) |
| NZ (1) | NZ572986A (enExample) |
| PL (1) | PL2044043T5 (enExample) |
| PT (1) | PT2044043E (enExample) |
| RS (1) | RS52205B2 (enExample) |
| SI (1) | SI2044043T2 (enExample) |
| TN (1) | TNSN08460A1 (enExample) |
| TW (1) | TWI443091B (enExample) |
| WO (1) | WO2007144005A1 (enExample) |
| ZA (1) | ZA200810017B (enExample) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| JP7179035B2 (ja) * | 2006-06-16 | 2022-11-28 | ハー・ルンドベック・アクチエゼルスカベット | 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン |
| BR122020011920A2 (pt) | 2006-06-16 | 2020-08-25 | Lundbeck & Co As H | composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto |
| TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TW200932233A (en) | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| AU2014200364B2 (en) * | 2007-11-13 | 2015-09-17 | H. Lundbeck A/S | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
| TW201033181A (en) * | 2009-02-17 | 2010-09-16 | Lundbeck & Co As H | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
| GEP20135938B (en) * | 2009-04-24 | 2013-10-10 | H Lundbeck As | Liquid pharmaceutical formulations of 1-[2-(2,4-dimethylsulfanyl)phenyl]piperazine |
| MX2012002199A (es) * | 2009-08-24 | 2012-03-16 | Lundbeck & Co As H | Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]pip erazina. |
| WO2011136376A1 (ja) * | 2010-04-30 | 2011-11-03 | 武田薬品工業株式会社 | 腸溶性錠剤 |
| PL3650439T3 (pl) * | 2010-07-23 | 2021-06-28 | Grünenthal GmbH | Sole lub kokryształy 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenolu |
| TW201212918A (en) | 2010-08-23 | 2012-04-01 | Lundbeck & Co As H | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
| LT2800746T (lt) * | 2012-01-03 | 2019-06-10 | H. Lundbeck A/S | 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazino gavimo būdas |
| US9713594B2 (en) * | 2012-09-11 | 2017-07-25 | Bend Research, Inc. | Methods for making pharmaceutical solid dosage forms of spray-dried dispersions |
| CN104797566B (zh) * | 2012-09-19 | 2017-07-07 | 桑多斯股份公司 | 沃替西汀氢溴酸盐的新结晶形式 |
| CN104853755B (zh) * | 2012-12-13 | 2017-08-22 | H.隆德贝克有限公司 | 包含沃替西汀和多奈哌齐的组合物 |
| CN104995181B (zh) * | 2013-02-22 | 2017-03-08 | H.隆德贝克有限公司 | 沃替西汀生产方法 |
| EP2981520B1 (en) | 2013-04-04 | 2019-03-06 | LEK Pharmaceuticals d.d. | New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine |
| WO2014177491A1 (en) | 2013-04-29 | 2014-11-06 | Lek Pharmaceuticals D.D. | New solid form of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine hydrobromide |
| WO2014191548A1 (en) * | 2013-05-31 | 2014-12-04 | Lek Pharmaceuticals D.D. | New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine |
| AU2014286308B2 (en) * | 2013-07-01 | 2018-05-10 | Lek Pharmaceuticals D.D. | 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form |
| US20160200698A1 (en) * | 2013-09-12 | 2016-07-14 | Hangzhou Pushai Pharmaceutical Technology Co., Ltd | Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage |
| WO2015044963A1 (en) | 2013-09-30 | 2015-04-02 | Cadila Healthcare Limited | An amorphous vortioxetine and salts thereof |
| CN104650003A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 一种沃替西汀化合物 |
| EP2878596A1 (en) * | 2013-11-29 | 2015-06-03 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates |
| CA2933733A1 (en) | 2013-12-20 | 2015-06-25 | Connie Sanchez Morillo | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features |
| EP2894154A1 (en) | 2014-01-14 | 2015-07-15 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates |
| CN103788020B (zh) * | 2014-01-22 | 2015-11-04 | 苏州明锐医药科技有限公司 | 沃替西汀的制备方法 |
| CN103788019B (zh) * | 2014-01-22 | 2015-10-07 | 苏州明锐医药科技有限公司 | 沃替西汀的制备方法 |
| WO2015114395A1 (en) | 2014-01-31 | 2015-08-06 | Egis Gyógyszergyár Zrt. | Process for the preparation of vortioxetine salts |
| EP3114239A4 (en) * | 2014-03-05 | 2017-10-11 | Takeda Pharmaceutical Company Limited | Method for treating depression and major depressive disorder |
| EP2930171A1 (en) | 2014-04-07 | 2015-10-14 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate |
| CN104974110A (zh) * | 2014-04-10 | 2015-10-14 | 江苏豪森药业股份有限公司 | 1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪氢溴酸盐的新晶型及其制备方法和用途 |
| EP3137083A2 (en) * | 2014-04-28 | 2017-03-08 | Alembic Pharmaceuticals Limited | Novel polymorphic forms of vortioxetine and its pharmaceutically acceptable salts |
| CN105254590B (zh) * | 2014-05-09 | 2019-09-03 | 江苏豪森药业集团有限公司 | 沃替西汀氢溴酸盐晶型及其制备方法和用途 |
| CN104059030B (zh) | 2014-05-30 | 2016-05-04 | 镇江圣安医药有限公司 | [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途 |
| CN105198837B (zh) * | 2014-06-09 | 2018-05-04 | 上海医药工业研究院 | 一种沃替西汀氢溴酸盐晶体及其制备方法 |
| CN105218482B (zh) * | 2014-06-24 | 2018-04-06 | 杭州和泽医药科技有限公司 | 沃替西汀氢溴酸盐β晶型的制备方法 |
| CZ2014471A3 (cs) | 2014-07-08 | 2016-01-20 | Zentiva, K.S. | Způsob přípravy vortioxetinu |
| US9687484B2 (en) | 2014-07-18 | 2017-06-27 | Dipharma Francis S.R.L. | Crystalline forms of an antidepressant compound |
| CN105330614A (zh) * | 2014-08-04 | 2016-02-17 | 上海诺星医药科技有限公司 | 一种氢溴酸沃替西汀晶体及其制备方法 |
| CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
| CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
| CN104292183B (zh) * | 2014-09-29 | 2016-01-06 | 杨献美 | 一种抗抑郁药物沃替西汀的制备方法 |
| US20170333424A1 (en) * | 2014-10-24 | 2017-11-23 | Hexal Ag | Amorphous Vortioxetine Hydrobromide |
| CN105669594A (zh) * | 2014-11-19 | 2016-06-15 | 康普药业股份有限公司 | 抗抑郁症药1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪的制备方法 |
| ES2634496T3 (es) | 2014-11-21 | 2017-09-28 | Dipharma Francis S.R.L. | Proceso para la preparación de un antidepresivo y los intermedios del mismo |
| CN104356092B (zh) * | 2014-11-27 | 2017-03-22 | 合肥创新医药技术有限公司 | 沃替西汀的制备方法 |
| CN104447622B (zh) * | 2014-11-28 | 2017-01-04 | 郑州大明药物科技有限公司 | 氢溴酸沃替西汀β晶型的制备方法 |
| CN105777667A (zh) * | 2014-12-18 | 2016-07-20 | 康普药业股份有限公司 | 抗抑郁症药1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪的制备方法 |
| CN105801517A (zh) * | 2014-12-30 | 2016-07-27 | 上海奥博生物医药技术有限公司 | 一种沃替西汀氢溴酸盐新晶型及其制备方法 |
| CZ201531A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Polymerem stabilizované amorfní formy vortioxetinu |
| CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
| CN104644594A (zh) * | 2015-02-03 | 2015-05-27 | 郑州大明药物科技有限公司 | 一种氢溴酸沃替西汀胃溶片及其制备方法 |
| WO2016125191A2 (en) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Processes for the preparation of vortioxetine hydrobromide |
| WO2016125190A2 (en) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof |
| AU2016224930A1 (en) | 2015-02-25 | 2017-09-07 | Lupin Limited | Process for the preparation of Vortioxetine |
| CN104650004B (zh) * | 2015-03-06 | 2017-06-06 | 中山万汉制药有限公司 | 一种氢溴酸沃替西汀的制备方法 |
| CN104628677A (zh) * | 2015-03-16 | 2015-05-20 | 浙江大学 | 一种沃替西汀有机酸盐晶型及其制备方法 |
| EP3274330A1 (en) | 2015-03-26 | 2018-01-31 | Cipla Limited | Method for making serotonin reuptake inhibitors |
| CN105367515B (zh) * | 2015-05-08 | 2017-10-27 | 北京北陆药业股份有限公司 | 一种氢溴酸沃替西汀α晶型的制备方法 |
| CN106279065A (zh) * | 2015-05-12 | 2017-01-04 | 北京深蓝海生物医药科技有限公司 | 一种氢溴酸沃替西汀的精制转晶方法 |
| JO3456B1 (ar) * | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
| CN104910099B (zh) * | 2015-05-22 | 2017-03-08 | 扬子江药业集团有限公司 | 一种氢溴酸沃替西汀晶体的制备方法 |
| CN106316986B (zh) * | 2015-07-03 | 2019-02-05 | 成都弘达药业有限公司 | 一种1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪氢溴酸盐α型晶体的制备方法 |
| CN105111167A (zh) * | 2015-08-06 | 2015-12-02 | 华南理工大学 | 一种沃替西汀半盐酸盐及其制备方法和药物组合物 |
| CN105061364A (zh) * | 2015-08-17 | 2015-11-18 | 河北国龙制药有限公司 | 氢溴酸沃替西汀的制备方法 |
| EP3337789A1 (en) * | 2015-08-19 | 2018-06-27 | Amneal Pharmaceuticals Company GmbH | Process for preparation of vortioxetine hydrobromide |
| CN105153066B (zh) * | 2015-09-07 | 2018-01-09 | 浙江大学 | 盐酸沃替西汀的结晶型物及其制备方法 |
| CN106632145B (zh) * | 2015-11-04 | 2021-11-05 | 江苏豪森药业集团有限公司 | 沃替西汀氢溴酸盐晶型α的新制备方法 |
| CN106674153A (zh) * | 2015-11-05 | 2017-05-17 | 浙江京新药业股份有限公司 | 沃替西汀半盐酸盐晶体及其组合物与制备和应用 |
| CN105294554B (zh) * | 2015-11-18 | 2017-11-07 | 乳源瑶族自治县大众药品贸易有限公司 | 苯基哌嗪衍生物及其使用方法和用途 |
| GB2557867A (en) * | 2015-11-18 | 2018-07-04 | Azad Pharmaceutical Ingredients Ag | New synthetic path to vortioxetine salts |
| US11013830B2 (en) * | 2015-11-20 | 2021-05-25 | Institut Pasteur | 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential |
| EP3184102A1 (en) | 2015-12-23 | 2017-06-28 | Hexal AG | Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound |
| EP3184104B1 (en) | 2015-12-23 | 2018-09-12 | Hexal AG | Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix |
| US20190194154A1 (en) * | 2016-01-20 | 2019-06-27 | Amneal Pharmaceuticals Company Gmbh | Polymorphic Forms Of Vortioxetine Hydrobromide Tert-Butanolate |
| WO2017154016A1 (en) * | 2016-03-07 | 2017-09-14 | Msn Laboratories Private Limited | Novel crystalline polymorphs of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide and process for preparation thereof |
| WO2017162536A1 (en) | 2016-03-21 | 2017-09-28 | H. Lundbeck A/S | Vortioxetine prodrugs |
| CA3018402C (en) * | 2016-03-29 | 2021-05-11 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | Vortioxetine pamoic acid salt and crystal form thereof |
| WO2017215636A1 (zh) * | 2016-06-16 | 2017-12-21 | 广东东阳光药业有限公司 | 二芳基硫醚哌嗪类化合物及其制备方法和用途 |
| MA45532A (fr) | 2016-07-01 | 2019-05-08 | H Lundbeck As | Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur |
| US20190290641A1 (en) * | 2016-07-15 | 2019-09-26 | Institut Pasteur | 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair |
| CN106243062A (zh) * | 2016-07-31 | 2016-12-21 | 合肥远志医药科技开发有限公司 | 一种沃替西汀工业化生产方法 |
| US20190224192A1 (en) | 2016-08-29 | 2019-07-25 | Cipla Limited | Stable Pharmaceutical Composition of Vortioxetine Hydrobromide |
| WO2018065348A1 (en) | 2016-10-05 | 2018-04-12 | Hexal Ag | Novel enteric-coated tablet comprising vortioxetine |
| CN107954947A (zh) * | 2016-10-14 | 2018-04-24 | 北京莱瑞森医药科技有限公司 | 沃替西汀氢溴酸盐晶型c及其制备方法 |
| US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
| US10428033B2 (en) | 2017-02-15 | 2019-10-01 | Piramal Enterprises Limited | Process for the preparation of vortioxetine and salts thereof |
| US11020390B2 (en) * | 2017-02-17 | 2021-06-01 | Unichem Laboratories Ltd | Bioequivalent pharmaceutical composition of vortioxetine hydrobromide |
| EP3585388A4 (en) * | 2017-02-23 | 2020-08-12 | Unichem Laboratories Ltd | IMPROVED PROCESS FOR PREPARATION AND PURIFICATION OF VORTIOXETINE BROMHYDRATE |
| KR102551433B1 (ko) | 2017-04-25 | 2023-07-04 | 하. 룬드벡 아크티에셀스카브 | 보르티옥세틴 hbr 알파-형태의 제조 방법 |
| EP3412661A1 (en) | 2017-06-08 | 2018-12-12 | Enantia, S.L. | Cocrystals of vortioxetine hydrobromide and resorcinol |
| KR102026337B1 (ko) | 2017-07-07 | 2019-09-27 | 영진약품 주식회사 | 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법 |
| CN109503517A (zh) * | 2017-09-14 | 2019-03-22 | 万全万特制药（厦门）有限公司 | 一种沃替西汀α晶型的制备方法 |
| JP6876586B2 (ja) * | 2017-09-27 | 2021-05-26 | Ｔｏｗａ株式会社 | 加工装置 |
| CN109928941A (zh) * | 2017-12-19 | 2019-06-25 | 成都弘达药业有限公司 | 一种氢溴酸沃替西汀的结晶化合物及其制备方法 |
| CN108017595A (zh) * | 2017-12-20 | 2018-05-11 | 安徽源久源科技有限公司 | 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法 |
| US10111873B1 (en) | 2018-01-17 | 2018-10-30 | King Saud University | Dihydropyrimidinone derivatives |
| EP3762371A1 (en) * | 2018-02-06 | 2021-01-13 | Piramal Enterprises Limited | An improved process for the preparation of vortioxetine and salts thereof |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN109535050A (zh) * | 2018-12-14 | 2019-03-29 | 合肥创新医药技术有限公司 | 一种1,2-双（（2,4-二甲基苯基）硫基）苯的制备方法 |
| JP2022540249A (ja) | 2019-09-04 | 2022-09-14 | シーズンズ バイオテクノロジー （タイジョウ） カンパニー リミテッド | ボルチオキセチン臭化水素酸塩を含む口腔内味マスキング用コーティング顆粒、固体分散体及び製剤 |
| TR202001040A2 (tr) * | 2020-01-23 | 2021-07-26 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vorti̇okseti̇n hi̇drobromi̇di̇n kri̇stali̇n c formu |
| AU2021246973A1 (en) | 2020-04-03 | 2022-11-03 | H. Lundbeck A/S | 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting |
| KR102455000B1 (ko) | 2020-07-06 | 2022-10-17 | 원광대학교산학협력단 | 피페라진 화합물 및 이의 제조 방법 |
| CN112006995A (zh) * | 2020-08-14 | 2020-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种氢溴酸伏硫西汀片的制备方法 |
| CN114075154B (zh) * | 2020-08-20 | 2025-03-28 | 正大天晴药业集团股份有限公司 | 伏硫西汀的制备方法 |
| US12281088B2 (en) | 2020-09-10 | 2025-04-22 | Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd | Process for the synthesis of vortioxetine |
| CN112125868B (zh) * | 2020-09-25 | 2021-08-03 | 中山万远新药研发有限公司 | 一种氢溴酸伏硫西汀晶型及其制备方法、组合物与用途 |
| WO2023036820A1 (en) | 2021-09-10 | 2023-03-16 | H. Lundbeck A/S | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
| CN116836132A (zh) * | 2022-03-23 | 2023-10-03 | 浙江华海药业股份有限公司 | 一种沃替西汀氢溴酸盐晶型h及其制备方法和用途 |
| CN115160258B (zh) * | 2022-06-24 | 2023-11-17 | 辰欣药业股份有限公司 | 一种氢溴酸沃替西汀γ晶型的制备方法 |
| GB2622880A (en) | 2022-09-30 | 2024-04-03 | Alkaloid Ad Skopje | Palatable orodispersible formulation of vortioxetine |
| JP7632902B2 (ja) | 2023-02-10 | 2025-02-19 | 株式会社Dhq | タキシフォリン含有組成物 |
| CN116589434A (zh) * | 2023-05-22 | 2023-08-15 | 山东泰合医药科技有限公司 | 一种伏硫西汀昔萘酸盐晶型a及其制备方法与应用 |
| WO2025132869A1 (en) | 2023-12-21 | 2025-06-26 | H. Lundbeck A/S | Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| WO1994020091A1 (en) | 1993-03-05 | 1994-09-15 | Hexal Pharma Gmbh | Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation |
| JPH07110050A (ja) | 1993-10-13 | 1995-04-25 | Daikin Mfg Co Ltd | 捩じり振動減衰装置 |
| ATE294778T1 (de) | 1995-01-23 | 2005-05-15 | Daiichi Suntory Pharma Co Ltd | Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen |
| AU4918796A (en) | 1995-02-10 | 1996-08-27 | Eli Lilly And Company | Methods of treating or preventing psychiatric disorders |
| ES2193607T3 (es) | 1998-01-16 | 2003-11-01 | Hoffmann La Roche | Derivados de benzosulfona . |
| WO1999061027A1 (en) | 1998-05-22 | 1999-12-02 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
| JP5035813B2 (ja) | 1998-07-10 | 2012-09-26 | マサチューセッツ インスティテュート オブ テクノロジー | 金属用のリガンドおよびそれらに基づいて改善された金属触媒法 |
| ES2154605B1 (es) | 1999-09-14 | 2001-11-16 | Univ Madrid Complutense | Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3 |
| UA77650C2 (en) | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| MXPA02006223A (es) | 1999-12-30 | 2002-12-05 | Lundbeck & Co As H | Derivados de fenilpiperazina sustituida, su preparcion y uso. |
| PE20020063A1 (es) | 2000-06-20 | 2002-01-30 | Upjohn Co | Bis-arilsulfonas como ligandos del receptor de 5-ht |
| UA76130C2 (en) | 2000-11-20 | 2006-07-17 | Merck Patent Gmbh | Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome |
| ATE340786T1 (de) | 2000-11-28 | 2006-10-15 | Pfizer Prod Inc | Salze eines 4-isothiazolcarboxamids und ihre verwendung als anti-hyperproliferationsmittel |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| DE60219521T2 (de) | 2001-12-20 | 2007-08-16 | H. Lundbeck A/S | Aryloxyphenyl und arylsulfanylphenylderivate |
| AU2003236500B9 (en) | 2002-06-12 | 2009-07-02 | Chemocentryx, Inc. | 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders |
| CA2521258C (en) * | 2003-04-04 | 2009-12-01 | H. Lundbeck A/S | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
| US9029363B2 (en) * | 2003-04-30 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Telmisartan sodium salt pharmaceutical formulation |
| US7893261B2 (en) | 2004-03-26 | 2011-02-22 | Baylor University | Serotonin reuptake inhibitors |
| EP1846359A4 (en) | 2005-01-06 | 2010-03-31 | Cj Cheiljedang Corp | INORGANIC ACID SALTS OF SIBUTRAMINE |
| CN1270776C (zh) | 2005-05-08 | 2006-08-23 | 纪辉 | 治疗粘膜溃疡的药物组合物，其制备和用途 |
| AU2007260356B2 (en) | 2006-06-16 | 2013-01-24 | H. Lundbeck A/S | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| BR122020011920A2 (pt) | 2006-06-16 | 2020-08-25 | Lundbeck & Co As H | composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto |
| TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TW200938194A (en) | 2007-12-14 | 2009-09-16 | Lundbeck & Co As H | Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter |
| CN104797566B (zh) | 2012-09-19 | 2017-07-07 | 桑多斯股份公司 | 沃替西汀氢溴酸盐的新结晶形式 |
-
2007
- 2007-06-15 BR BR122020011920A patent/BR122020011920A2/pt not_active Application Discontinuation
- 2007-06-15 ZA ZA200810017A patent/ZA200810017B/xx unknown
- 2007-06-15 KR KR1020137013877A patent/KR101445514B1/ko active Active
- 2007-06-15 WO PCT/DK2007/050075 patent/WO2007144005A1/en not_active Ceased
- 2007-06-15 MX MX2008016141A patent/MX2008016141A/es active IP Right Grant
- 2007-06-15 PL PL07764495T patent/PL2044043T5/pl unknown
- 2007-06-15 PT PT07764495T patent/PT2044043E/pt unknown
- 2007-06-15 EP EP11193235.6A patent/EP2439201B1/en active Active
- 2007-06-15 BR BR122020011899-7A patent/BR122020011899B1/pt active IP Right Grant
- 2007-06-15 AT AT07764495T patent/ATE540941T1/de active
- 2007-06-15 AU AU2007260355A patent/AU2007260355B2/en active Active
- 2007-06-15 US US12/301,061 patent/US8722684B2/en active Active
- 2007-06-15 ES ES11193235T patent/ES2432102T3/es active Active
- 2007-06-15 RS RS20120107A patent/RS52205B2/sr unknown
- 2007-06-15 KR KR1020087030668A patent/KR20090028712A/ko not_active Ceased
- 2007-06-15 CA CA2655212A patent/CA2655212C/en active Active
- 2007-06-15 AR ARP070102641A patent/AR061481A1/es active IP Right Grant
- 2007-06-15 NZ NZ572986A patent/NZ572986A/en unknown
- 2007-06-15 EP EP07764495.3A patent/EP2044043B2/en active Active
- 2007-06-15 BR BRPI0713425-8A patent/BRPI0713425A2/pt not_active Application Discontinuation
- 2007-06-15 MY MYPI20084778 patent/MY150647A/en unknown
- 2007-06-15 SI SI200730876T patent/SI2044043T2/sl unknown
- 2007-06-15 CN CN201210034695.6A patent/CN102614179B/zh active Active
- 2007-06-15 KR KR1020137029366A patent/KR101627901B1/ko active Active
- 2007-06-15 HR HRP20120173TT patent/HRP20120173T4/hr unknown
- 2007-06-15 CN CN2007800223385A patent/CN101472906B/zh active Active
- 2007-06-15 FI FIEP07764495.3T patent/FI2044043T5/fi active
- 2007-06-15 DK DK07764495.3T patent/DK2044043T4/da active
- 2007-06-15 ES ES07764495T patent/ES2379200T5/es active Active
- 2007-06-15 EA EA200970018A patent/EA015287B1/ru active Protection Beyond IP Right Term
- 2007-06-15 JP JP2009514642A patent/JP4590013B2/ja active Active
- 2007-06-15 CN CN201210034684.8A patent/CN102617513B/zh active Active
- 2007-06-20 TW TW096122001A patent/TWI443091B/zh active
-
2008
- 2008-11-17 TN TNP2008000460A patent/TNSN08460A1/en unknown
- 2008-11-25 IL IL195511A patent/IL195511A/en active IP Right Grant
-
2009
- 2009-01-06 MA MA31550A patent/MA30575B1/fr unknown
- 2009-01-16 NO NO20090229A patent/NO343929B1/no active IP Right Maintenance
- 2009-12-25 JP JP2009295187A patent/JP5702929B2/ja active Active
-
2011
- 2011-06-29 CL CL2011001610A patent/CL2011001610A1/es unknown
-
2012
- 2012-03-08 CY CY20121100240T patent/CY1112635T1/el unknown
- 2012-11-28 JP JP2012259835A patent/JP5763609B2/ja active Active
-
2014
- 2014-04-01 US US14/242,337 patent/US9227946B2/en active Active
- 2014-04-01 US US14/242,510 patent/US9125908B2/en active Active
- 2014-04-29 US US14/264,373 patent/US9101626B2/en active Active
- 2014-07-09 US US14/326,725 patent/US9125909B2/en active Active
- 2014-08-29 US US14/472,896 patent/US9095588B2/en active Active
- 2014-09-09 US US14/481,000 patent/US9125910B2/en active Active
- 2014-09-09 US US14/480,949 patent/US8969355B2/en active Active
-
2015
- 2015-06-11 JP JP2015118179A patent/JP6101742B2/ja active Active
- 2015-11-23 US US14/948,775 patent/US20160083359A1/en not_active Abandoned
-
2016
- 2016-08-19 JP JP2016161018A patent/JP2017008086A/ja not_active Withdrawn
-
2017
- 2017-08-10 US US15/674,043 patent/US9861630B1/en active Active
- 2017-12-18 US US15/845,677 patent/US20180333408A1/en not_active Abandoned
-
2018
- 2018-08-09 JP JP2018150653A patent/JP6724082B2/ja active Active
-
2019
- 2019-07-03 US US16/502,677 patent/US11458134B2/en active Active
-
2022
- 2022-09-20 US US17/949,188 patent/US20230021520A1/en active Pending
- 2022-11-15 JP JP2022182209A patent/JP2023009175A/ja not_active Withdrawn
-
2024
- 2024-10-31 JP JP2024191303A patent/JP2025021476A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009541216A5 (enExample) | ||
| JP2010529118A5 (enExample) | ||
| JP2010518061A5 (enExample) | ||
| JP2017527578A5 (enExample) | ||
| HRP20192032T1 (hr) | Supstituirani 2-azabicikli i njihova upotreba kao modulatora receptora oreksina | |
| FI3856341T3 (fi) | (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä | |
| JP2009506014A5 (enExample) | ||
| JP2015145426A5 (enExample) | ||
| JP2010522242A5 (enExample) | ||
| JP2013237682A5 (enExample) | ||
| GEP20227366B (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| JP2017526711A5 (enExample) | ||
| NZ592961A (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| JP2014502641A5 (enExample) | ||
| UA90545C2 (ru) | Твердая фармацевтическая лекарственная форма для перорального введения с быстрым высвобождением ингибитора фактора ха свертывания крови | |
| JP2010514806A5 (enExample) | ||
| JP2010514807A5 (enExample) | ||
| JP2017529332A5 (enExample) | ||
| JP2011524850A5 (enExample) | ||
| JP2016503010A5 (enExample) | ||
| JP2006524700A5 (enExample) | ||
| CA2656057A1 (en) | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain | |
| NZ598083A (en) | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine | |
| MX2011010732A (es) | Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer. | |
| JP2012531402A5 (enExample) |